Keywords: \shire, Heptares, Adenosie A2A antagonist, Parkinson's, CNS diseases
Shire gets exclusive option for Heptares A2A program for CNS diseases
Article | 10 May 2011
Closely-held UK-based drug discovery firm Heptares Therapeutics says it has signed an exclusive option agreement with Ireland-headquartered Shire (LSE: SHP) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
